First Time Loading...

Burning Rock Biotech Ltd
NASDAQ:BNR

Watchlist Manager
Burning Rock Biotech Ltd Logo
Burning Rock Biotech Ltd
NASDAQ:BNR
Watchlist
Price: 0.97 USD +4.3% Market Closed
Updated: Sep 30, 2023

Intrinsic Value

Intrinsic Value History
Burning Rock Biotech Ltd

Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.

This feature available only with
Unlimited Plan

Sign up to access Burning Rock Biotech Ltd's intrinsic value history.

No restrictions, no limits.
All stocks, all tools.

Example
Spot Contrarian Opportunities

Look for stocks that have been historically overvalued but are now trading below their intrinsic value.

Example
Easily Identify Value Traps

Avoid stocks that are always undervalued and never reach their intrinsic value.

Example
Find Strong Rebounds

Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.

Valuation Methods

There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.

DCF Value
Discounted Cash Flow

DCF Parameters:
Operating Model
Discount Rate
Forecast Period
Terminal Growth
DCF Input
DCF Input
DCF Input

Fundamental Analysis

Financials

Balance Sheet Decomposition
Burning Rock Biotech Ltd

Current Assets 1.1B
Cash & Short-Term Investments 733m
Receivables 202m
Other Current Assets 155m
Non-Current Assets 241m
Long-Term Investments 505k
PP&E 222m
Intangibles 1.2m
Other Non-Current Assets 17m
Current Liabilities 353m
Accounts Payable 24.6m
Accrued Liabilities 180m
Other Current Liabilities 149m
Non-Current Liabilities 10.1m
Other Non-Current Liabilities 10.1m
Efficiency
Fundamental Scores

BNR Profitability Score
Profitability Due Diligence

Burning Rock Biotech Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
ROE is Increasing
Exceptional Revenue Growth Forecast
28/100
Profitability
Score

Burning Rock Biotech Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

BNR Solvency Score
Solvency Due Diligence

Burning Rock Biotech Ltd's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
47/100
Solvency
Score

Burning Rock Biotech Ltd's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BNR Price Targets Summary
Burning Rock Biotech Ltd

Wall Street analysts forecast BNR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BNR is 5.71 USD .

Lowest
Price Target
Not Available
Average
Price Target
5.71 USD
489% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

BNR Return Decomposition
Main factors of price return

What is price return decomposition?

BNR Price
Burning Rock Biotech Ltd

1M 1M
-29%
6M 6M
-67%
1Y 1Y
-59%
3Y 3Y
-96%
5Y 5Y
-96%
10Y 10Y
-96%
Annual Price Range
0.97
52w Low
0.91
52w High
3.47
Price Metrics
Average Annual Return -29.45%
Standard Deviation of Annual Returns 40.61%
Max Drawdown -98%
Shares Statistics
Market Capitalization 99.6m USD
Shares Outstanding 102 675 000
Percentage of Shares Shorted 5.22%

Company Profile

Burning Rock Biotech Ltd Logo
Burning Rock Biotech Ltd

Country

China

Industry

Biotechnology

Market Cap

99.6m USD

Dividend Yield

0%

Description

Burning Rock Biotech Ltd. engages in the investment of medical fields. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2020-06-12. The firm operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The firm mainly conducts its businesses in the China market.

Contact

GUANGDONG
Guangzhou
No. 5 Xingdao Ring Road North,, International Bio Island
+8618501641666.0
http://www.brbiotech.com/

IPO

2020-06-12

Employees

938

Officers

Chief Scientific Officer & Director
Dr. Shaokun Chuai
Founder, Chairman & CEO
Mr. Yusheng Han
CFO, Compliance Officer & Director
Mr. Jinxiang Li
Chief Technology Officer
Dr. Zhihong Zhang
Sr. Advisor
Mr. Hao Liu

See Also

Other Stocks
What is the Intrinsic Value of one BNR stock?

The intrinsic value of one BNR stock under the Base Case scenario is 6.99 USD.

Is BNR stock undervalued or overvalued?

Compared to the current market price of 0.97 USD, Burning Rock Biotech Ltd is Undervalued by 86%.